Idarubicin

Research use only, not for human use.

Idarubicin (4-Demethoxydaunorubicin;IMI-30;NSC 256439) is an anthracycline antileukemic that inserts into DNA and prevents DNA unwinding by interfering with the enzyme Topoisomerase II in cancer cells.

Idarubicin (4-Demethoxydaunorubicin;IMI-30;NSC 256439) is an anthracycline antileukemic that inserts into DNA and prevents DNA unwinding by interfering with the enzyme Topoisomerase II in cancer cells; inhibits the proliferation of MCF-7 cells with IC50 of 0.1 uM; also induces histone eviction from chromatin.Chemotherapeutic Agents Approved.

The IC50 of idarubicin is 3.3 ± 0.4 ng/mL on MCF-7 monolayers and 7.9 ± 1.1 ng/mL in multicellular spheroids. Idarubicin shows a greater cytotoxicity than daunorubicin or doxorubicin in various in vitro systems. This has been attributed to a better ability of idarubicin to induce the formation of topoisomerase II -mediated DNA breaks.Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively. Idarubicin produces a concentration-dependent reduction in MCF-7 cell growth, with an IC50 of approximately 0.01 μM. Idarubicin produces a concentration-dependent inhibition of DNA synthesis and a time- and concentration-dependent suppression of c-myc expression.

——

4-Demethoxydaunorubicin | IMI-30 | NSC 256439

Cell Cycle/DNA Damage

Topoisomerase

Topoisomerase

Cancer

Chemotherapeutic

58957-92-9

497.494

C26H27NO9

>98% (HPLC)

——

CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O

(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione

(-20℃)

With Ice Pack

≥ 2 years